Member Info for Badsterman

A January 2023 overview of RAS development and future outlook.
Includes a table of peptide and peptidomimetic RAS binders and their properties.

https://portlandpress.com/biochemsoctrans/article/doi/10.1042/BST20221343/232483/Eliminating-oncogenic-RAS-back-to-the-future-at

Let's hope for positive Barcelona results.

I'm going for;

1. Some modest diamond sales.
2. Stockpile of HMS, hopefully with a buyer/contract announcement.
3. Progess on the licence application for the adjoining beach.
4. More cash from China.
5. Kenya update.

An ambitious 1.5p - 1.7p

GLA

Sooty,

It's simple;

The legacy assets are a tough sell and Suzy gave it her best shot.

In the meantime she's hired new talent, delivered three evaluations and a lab to follow.

The business is heading in a different direction and no amount of bleating about legacy assets is going to change that.

Oh, I agree with TDK - those of you poking fun at Suzy are pathetic.

End.

OK Hoosier, I'll take it back.

I'm not interested in mud slinging.

Let's start with 201 - a 6 year trial, containing 12 patients with limited clinical data.

An easy sell, right?

Come on lads, you heard the Q&A - the legacy data ain't cutting it.

The business has clearly signposted that it's going in a different direction.

If you don't like it follow Mr Slater and sell.

Ice - Suzy's tried her level best to commercialise legacy assets, with very average data, against a background of stringent regulatory requirements and COVID delays.

Yet in three years Valirx have attracted top draw personnel, three cutting edge evaluations and a lab is coming on stream.

Accusing Suzy of "no urgency" is rather harsh.

Sooty - I don't know what Adam saw in the data, but I do know even industry leading experts get it wrong - see SNG, for example.

Northern,

Doing her level best to commercialise assets with the sub-standard data left by the previous regime?

Come on Ells,

Valirx are clearly in a transitional period.

I accept the spectre of an additional fundraise is hanging over us. However, Valirx needs to be fit and ready for the new strategy.

The Board made it obvious that the years of clinging to the legacy assets are over, irrespective of what shareholders think.

https://twitter.com/DillySuzy/status/1620369845132087297?t=oTcB5vgP5KWJQB4NzK8tgg&s=19

Giant are a subsidiary of Ahold Delhaize , who are a big fish, with 6,500 stores in 11 countries.

A very promising RNS.

Not sure I agree;

Bigger wage bill
Higher fixed cost base
Resolution 4
No income
Major shareholder exiting

If there isn't a positive RNS soon there'll only be tiny MCAP left to dilute.

I feel certain the Board must have some good news up their sleeves.

I'm eagerly awaiting the latest data from the HMS operation.

Although it's bad form to wish one's life away, especially on AIM!!

GLA holders.

https://www.brrmedia.co.uk/broadcasts-embed/63d17647777efd4a8b516102/valirx-qa/?popup=true

The next red dot will be the passing of all AGM resolutions.

The subsequent red dot will be another fund raise.

Followed by an "Operational Update" RNS filled with the usual can kicking descriptors and TRX platitudes.

The wait goes on...and on...

Buda,

It seems you're happy for yet another "jam tomorrow" Q&A in the face of impending raise(s)?

It's pre-recorded so they can include some carefully vetted statements, particularly about the need for resolution four.

The Board need to start earning their keep.

Agreed Pudycat,

Patience is wearing thin amongst many.

The legacy programme has stalled completely, whilst the payroll gets bigger with yet more raises on the horizon re: clause 4.

If the usual bland tropes are served up in the Q&A it won't go down well.

Something solid is needed, and soon.

Maybe something behind the scenes has triggered TEK's decision to convert.

An RNS with a multi-million dollar Microsalt contract would suffice!! Ha!

GLA.

No,

TEK previously lent Microsalt $1.35 million. They've converted the loan into shares, in all probability due to the impending IPO.

Explanation for you;

https://tinyurl.com/bdfcuczj

"Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products that can improve people's lives, is pleased to announce that it has converted its outstanding convertible loan note of c.US$1.35m in MicroSalt's U.S. operating subsidiary, MicroSalt Inc. at a value of US$2.18 per share. This values MicroSalt at US$ 20.0m"

IPO inching closer...